Effects of Tofacitinib, an Oral Janus Kinase Inhibitor, on Active Ulcerative Colitis

Ulcerative colitis is a long-term inflammatory disorder of the colon and rectum. Study found, tofacitinib to be more effective than placebo in reducing disease activity.

Ulcerative colitis is a long-term inflammatory disorder of the large intestine (colon) and rectum. There is no effective therapy which works in all patients of ulcerative colitis. In a recent study, tofacitinib (CP-690,550), a selective Janus kinases inhibitor was evaluated for its effectiveness against ulcerative colitis. By blocking Janus kinases, the drug inhibits the inflammatory process of ulcerative colitis.

This multi-center, phase 2 clinical trial was conducted on 194 patients ≥ 18 years with a diagnosis of ulcerative colitis for at least 3 months. Over 8 weeks, the active ulcerative colitis patients were treated with twice-a-day 0.5 mg to 15 mg of tofacitinib or placebo. The main outcome was a reduction in ulcerative colitis activity and rectal bleeding as per the Mayo score, which measures the disease severity on a 0-12 scale. Patients continued to receive oral mesalamine or prednisone daily. Colonoscopy was conducted at 0 and 8 week time-points.

Ulcerative Colitis
Ulcerative colitis is characterized by bouts of diarrhea, bleeding per rectum and pain, which remits and relapses. Fulminant colitis is a possibility, which may require colectomy.

The study results showed that after 8 weeks, ulcerative colitis activity decreased by 32%, 48%, 61%, and 78% in patients treated with 0.5 mg, 3 mg, 10 mg and 15 mg tofacitinib, respectively. A 42% decrease in ulcerative colitis activity was also observed in placebo-treated patients. On the other hand, clinical remission was seen in 13%, 33%, 48%, and 41% of patients receiving 0.5 mg, 3 mg, 10 mg and 15 mg tofacitinib, respectively, while 10% placebo-treatment patients showed clinical remission.

Common serious side-effects of tofacinitib included influenza and nasopharyngitis. Other side effects were a decrease in neutrophil count (a type of white blood cell) and increase in LDL-cholesterol levels.

In conclusion, patients with active moderate or severe ulcerative colitis treated with high doses tofacitinib had a clinical response and clinical remission more frequently than those receiving placebo. The role of tofacitinib in maintenance therapy has not been established. Larger studies are required to establish the benefits and adverse effects of tofacitinib in active ulcerative colitis.

Drugs for Ulcerative Colitis
View list of generic and brand names of drugs used for treatment of Ulcerative Colitis. Find more information including dose, side effects of the Ulcerative Colitis medicine.

Reference: Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis; William Sandborn et al; N Engl J Med 2012; 367:616-624

Source-Medindia

Ulcerative Colitis - Treatment of Ulcerative Colitis
Salazopyrine derivatives and steroids are commonly used in the treatment of ulcerative colitis. Surgery is reserved for severe, life threatening cases not responding to medication.

Colonoscopy Versus Fecal Immunochemical Testing in Colorectal-Cancer
Fecal Immunochemical Testing (FIT) is usually preferred by people for screening of colorectal cancer. But a higher number of lesions can be detected more clearly using colonoscopy.